Susanne Schüler-Toprak1, Florian Weber2, Maciej Skrzypczak3, Olaf Ortmann4, Oliver Treeck4. 1. Department of Gynecology and Obstetrics, University Medical Center Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. Susanne.Schueler@klinik.uni-regensburg.de. 2. Department of Pathology, University Medical Center Regensburg, Franz-Josef Strauß Allee11, 93053, Regensburg, Germany. 3. Second Department of Gynecology, Medical University of Lublin, Jaczewskiego 8, 20-090, Lublin, Poland. 4. Department of Gynecology and Obstetrics, University Medical Center Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.
Abstract
PURPOSE: This study further approaches the role of estrogen-related receptors (ERRs) in ovarian cancer. Protein expression of ERRα, ERRβ and ERRγ in ovarian cancer was assessed and was correlated with ovarian cancer markers, steroid hormone receptors and cancer-associated genes. Additionally, we examined to what extent expression of ERRs affects survival of ovarian cancer patients. METHODS: For this purpose, we established a tissue microarray from 208 ovarian cancer patients and performed immunohistochemical analyses of the mentioned proteins. RESULTS: ERRα and ERRγ protein could be detected at different levels in more than 90% of all ovarian cancer tissues, whereas expression of ERRβ was observed in 82.2% of the cases. ERRα was found to positively correlate with ovarian cancer marker CEA (p < 0.005) and ERRγ correlated with ERα (p < 0.001). Univariate survival analyses revealed that ERRα expression did not affect overall (OS) or progression-free survival (PFS) of ovarian cancer patients. In contrast, higher expression of ERRβ in serous ovarian cancers was found to lead to a significantly decreased OS (p < 0.05). The strongest impact on survival was exhibited by ERRγ. Lower expression of this receptor in women with serous ovarian cancers indicated significantly increased OS compared to those with higher levels of ERRγ (p < 0.05). Multivariate survival analyses revealed ERRγ as an independent prognostic marker regarding OS of patients with serous ovarian cancer. CONCLUSION: Our data demonstrating that ERR proteins are frequently expressed in ovarian cancer and high levels of ERRβ and ERRγ significantly decreased OS of serous ovarian cancer patients suggest that these proteins might be interesting therapy targets in this cancer entity.
PURPOSE: This study further approaches the role of estrogen-related receptors (ERRs) in ovarian cancer. Protein expression of ERRα, ERRβ and ERRγ in ovarian cancer was assessed and was correlated with ovarian cancer markers, steroid hormone receptors and cancer-associated genes. Additionally, we examined to what extent expression of ERRs affects survival of ovarian cancerpatients. METHODS: For this purpose, we established a tissue microarray from 208 ovarian cancerpatients and performed immunohistochemical analyses of the mentioned proteins. RESULTS:ERRα and ERRγ protein could be detected at different levels in more than 90% of all ovarian cancer tissues, whereas expression of ERRβ was observed in 82.2% of the cases. ERRα was found to positively correlate with ovarian cancer marker CEA (p < 0.005) and ERRγ correlated with ERα (p < 0.001). Univariate survival analyses revealed that ERRα expression did not affect overall (OS) or progression-free survival (PFS) of ovarian cancerpatients. In contrast, higher expression of ERRβ in serous ovarian cancers was found to lead to a significantly decreased OS (p < 0.05). The strongest impact on survival was exhibited by ERRγ. Lower expression of this receptor in women with serous ovarian cancers indicated significantly increased OS compared to those with higher levels of ERRγ (p < 0.05). Multivariate survival analyses revealed ERRγ as an independent prognostic marker regarding OS of patients with serous ovarian cancer. CONCLUSION: Our data demonstrating that ERR proteins are frequently expressed in ovarian cancer and high levels of ERRβ and ERRγ significantly decreased OS of serous ovarian cancerpatients suggest that these proteins might be interesting therapy targets in this cancer entity.
Authors: Mary A Dwyer; James D Joseph; Hilary E Wade; Matthew L Eaton; Rebecca S Kunder; Dmitri Kazmin; Ching-yi Chang; Donald P McDonnell Journal: Cancer Res Date: 2010-09-24 Impact factor: 12.701
Authors: Aws Abdul-Wahid; Marzena Cydzik; Nicholas W Fischer; Aaron Prodeus; John E Shively; Anne Martel; Samira Alminawi; Zeina Ghorab; Neil L Berinstein; Jean Gariépy Journal: Int J Cancer Date: 2018-08-09 Impact factor: 7.396
Authors: Karen K L Chan; Michelle K Y Siu; Yu-Xin Jiang; Jing-Jing Wang; Yan Wang; Thomas H Y Leung; Stephanie S Liu; Annie N Y Cheung; Hextan Y S Ngan Journal: BMC Cancer Date: 2017-08-31 Impact factor: 4.430
Authors: Monica De Luise; Manuela Sollazzo; Eleonora Lama; Camelia Alexandra Coadă; Licia Bressi; Maria Iorio; Beatrice Cavina; Luigi D'Angelo; Sara Milioni; Lorena Marchio; Stefano Miglietta; Sara Coluccelli; Greta Tedesco; Anna Ghelli; Silvia Lemma; Anna Myriam Perrone; Ivana Kurelac; Luisa Iommarini; Anna Maria Porcelli; Giuseppe Gasparre Journal: Sci Rep Date: 2022-05-16 Impact factor: 4.996